Established Products Fact Sheet
| Established Products Business Unit: | Pfizer's Established Products Business Unit (EPBU) was created in 2008 to provide underserved patients with affordable medicines characterized by Pfizer's reputation for quality, safety, and innovation. Led by David Simmons, President and General Manager, EPBU is a small, flexible unit that leverages Pfizer's strengths to manage the established product portfolio. Established products are medicines that have lost patent exclusivity or are close to losing their exclusivity. The Established Products Business Unit portfolio contains more than 600 products — both branded and generic — spanning a wide range of therapeutic areas. Pfizer's global sales of established products are more than $10 billion annually. |
|
|---|---|---|
| Established Products Business Unit Core Strategy: | Established products are traditionally a shrinking segment of business due to intense generic competition brought on by the loss of exclusivity (LOE) of the products. Pfizer's Established Products Business Unit is committed to stabilizing the current base business and transforming it into growth, through strategies like product enhancements and reformulations; portfolio expansion; licensing and marketing non-Pfizer molecules; competing in żnicheż markets like sterile injectables; and managing late stage lifecycle planning for current products before loss of exclusivity. | |
| The global market for Established Products: | Overall, the global market for these products is big — and growing. In 2006, the established products market was $270B; within the next five years, it is expected to grow to over $500B. (Source: Evaluate-Pharma) | |
| Benefit to patients: | The off-patent marketplace worldwide too often suffers from quality and supply reliability issues. With its broad established products portfolio and capabilities in low-cost manufacturing, Pfizer is in an ideal position to supply high quality medicines at affordable prices. | |
| Pfizer's top-selling Established Products: |
Pfizer is proud of its extensive line of established products, which includes many familiar brands that have long served patients around the world. One such medicine, Solu-Medrol, recently celebrated its 50th birthday. Medicines like these are the foundation on which Pfizer's long-standing reputation for quality and great care for patients was built. Pfizer's established products range across a variety of therapeutic areas, including anti-infective, pain and inflammation, cardiovascular disease, central nervous system, and women's health. Some of the top-selling Pfizer Established Products are:
For more information, visit the Products section. |
|
| Pfizer Injectables: | Pfizer is already an established player in the injectable market, offering medicines from antibiotics to cancer therapies. Pfizer is committed to making these medicines accessible and affordable to patients. Current Pfizer injectable medicines include:
Pfizer is expanding its portfolio of injectables through agreements with other companies. New sterile injectables, such as antibiotics like cephalosporins and penicillins, will soon be available through these agreements. |
|
| Greenstone LLC: | Greenstone LLC, a subsidiary of Pfizer, manufactures and distributes generic versions of many Pfizer medicines, including several injectables. It also distributes non-Pfizer medicines through agreements with other pharmaceutical companies such as India-based Aurobindo. Greenstone has an established reputation for quality products and consistency of supply, and is the seventh-largest generic pharmaceutical company in the world by volume of prescriptions dispensed. | |
| Quality: | Pfizer's reputation depends on the quality and safety of the products it sells. Whether medicines are produced internally or through agreements with external sources, Pfizer takes an active role in ensuring a secure supply chain to protect the patients who use its products. Pfizer has a well established process in place to evaluate and qualify any external supplier. This process involves several levels of due diligence related to Quality and Supply Chain systems; the negotiation of Quality and Supply agreements; and extensive product testing. Once a supplier has been qualified, Pfizer conducts detailed oversight of performance to ensure standards are maintained. |
|
| Last Update: | January 7, 2010 |
Stock Quote Disclaimer
20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.
Stock Symbol: PFE Stock Exchange: NYSE
Stock Quote at: Sep 7 2010 4:00PM
| Last 16.33 | Change -0.13 |
| %Change | -0.79 | Vol. | 39,862,164 |
| Day High | 16.45 | 52 Wk. High | 20.36 |
| Day Low | 16.21 | 52 Wk. Low | 14.00 |
| Open | 16.45 | Mkt. Cap(Bil) | 131.27 |
| Prev. Close | 16.46 |
Pfizer. Where science comes to life. Where life meets science.
- View the Interactive 2009 Annual Report
- Learn more about Our Path Forward
- Contact Us
- Investors
- Sitemap
- Careers
- Business to Business
- Terms of Use
- Global Network
- Privacy Policy
Copyright © 2002–2010 Pfizer Inc. All rights reserved. This information is intended only for residents of the United States. The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries. Pfizer Inc is a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.
